Tri-Nasal Spray, administered intranasally, has been approved for the treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults & children 12 years of age or older. These symptoms include sneezing, stuffiness, discharge, and itching. Starting dose is 200 mcg for most patients, although dosing should be individualized based on such variables as degree of patient allergy and degree of pollen exposure.
Allergic rhinitis, otherwise known as hay fever, occurs when the immune system reacts to pollens and other allergens. Allergies can be hereditary or they can be triggered by environmental or even emotional conditions.
Eight controlled clinical trials investigated 746 patients with either perennial or seasonal allergic rhinitis. Results indicated that 200 mcg daily of the study drug significantly relieved nasal symptoms of the seasonal rhinitis. In one trial, only the 400 mcg dose (and not the 200 mcg dose) showed significant improvement of nasal symptoms over placebo.
In rare cases, the development of localized infections of the nose and pharynx has occurred.
It has been shown in clinical studies that intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients. Pediatric patients should therefore be monitored closely when taking this medication. Furthermore, children should be given the lowest effective dosage.
Other adverse events include:
Triamcinolone acetonide is a more potent derivative of triamcinolone. Triamcinolone acetonide is approximately eight times more potent than prednisone in animal models of inflammation.
Although the precise mechanism of corticosteroid antiallergic action is unknown, corticosteroids are very effective. When allergic symptoms are very severe, local treatment with recommended doses (microgram) of available topical corticosteroids are not as effective as treatment with larger doses (milligram) of oral or parenteral formulations. (From FDA Label)
Visit the web site of the Asthma and Allergy Foundation of America, a not-for-profit organization dedicated to finding a cure for and controlling asthma and allergic diseases: www.aafa.org
The Tri-Nasal Spray (triamcinolone acetonide spray) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.